Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lingdi Zhao

Showing results (31-40 of 59) with videos related to

Pageof 6
Sort By:
Frontiers in Immunology|May 25, 2026
Sequential versus concurrent neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a randomized, controlled, open-label, phase 2 trial (HCHTOG1906)Yan Zheng, Jiwei Wu, Lingdi Zhao, et al.
Immunotherapy|March 23, 2018
Survival benefit from RectroNectin-activated cytokine-induced killer cells combined with chemotherapy in advanced EGFR wild-type lung adenocarcinomaLingdi Zhao, Wei Li, Zibing Wang, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 10, 2013
Association of myeloid-derived suppressor cells and efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma patientsZibing Wang, Yong Zhang, Yuqing Liu, et al.
Journal of Leukocyte Biology|March 14, 2025
Utility of the neutrophil-to-lymphocyte ratio and the ratio of neutrophil-to-lymphocyte ratio after and before adverse events for differential diagnosis of immune-related adverse events and bacterial infections in cancer patients treated with PD-(L)1 inhibitorsLu Han, Beibei Huang, Linlin Li, et al.
Frontiers in Oncology|January 28, 2026
Predictors of postoperative recurrence in locally advanced gastric cancer patients achieving pathological complete response after neoadjuvant therapy: a matched case-control studyZhiqiang Jiang, Jiankai Lyu, Xiliang Cong, et al.
Immunotherapy|October 24, 2018
Combination of PD-1 blockade and RetroNectin<sup>®</sup>-activated cytokine-induced killer in preheavily treated non-small-cell lung cancer: a retrospective studyLingdi Zhao, Lu Han, Yong Zhang, et al.
Journal of Thoracic Disease|December 7, 2020
A phase II, single-centre trial of neoadjuvant toripalimab plus chemotherapy in locally advanced esophageal squamous cell carcinomaWenqun Xing, Lingdi Zhao, Xiaomin Fu, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|January 1, 2014
Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patientsShuai Wang, Xiaohong Han, Xingsheng Hu, et al.
Immunotherapy|December 15, 2018
Clinical value of neutrophil-to-lymphocyte ratio as a predictor of prognosis of RetroNectin<sup>®</sup>-activated cytokine-induced killer cell therapy in advanced non-small-cell lung cancerLingdi Zhao, Tiepeng Li, Yonghao Yang, et al.
Journal of Oncology|October 31, 2019
Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced MelanomaLingdi Zhao, Yonghao Yang, Baozhen Ma, et al.
Pageof 6

Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
Frontiers in Immunology|May 25, 2026
Sequential versus concurrent neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a randomized, controlled, open-label, phase 2 trial (HCHTOG1906)Yan Zheng, Jiwei Wu, Lingdi Zhao, et al.
Immunotherapy|March 23, 2018
Survival benefit from RectroNectin-activated cytokine-induced killer cells combined with chemotherapy in advanced EGFR wild-type lung adenocarcinomaLingdi Zhao, Wei Li, Zibing Wang, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 10, 2013
Association of myeloid-derived suppressor cells and efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma patientsZibing Wang, Yong Zhang, Yuqing Liu, et al.
Journal of Leukocyte Biology|March 14, 2025
Utility of the neutrophil-to-lymphocyte ratio and the ratio of neutrophil-to-lymphocyte ratio after and before adverse events for differential diagnosis of immune-related adverse events and bacterial infections in cancer patients treated with PD-(L)1 inhibitorsLu Han, Beibei Huang, Linlin Li, et al.
Frontiers in Oncology|January 28, 2026
Predictors of postoperative recurrence in locally advanced gastric cancer patients achieving pathological complete response after neoadjuvant therapy: a matched case-control studyZhiqiang Jiang, Jiankai Lyu, Xiliang Cong, et al.
Immunotherapy|October 24, 2018
Combination of PD-1 blockade and RetroNectin<sup>®</sup>-activated cytokine-induced killer in preheavily treated non-small-cell lung cancer: a retrospective studyLingdi Zhao, Lu Han, Yong Zhang, et al.
Journal of Thoracic Disease|December 7, 2020
A phase II, single-centre trial of neoadjuvant toripalimab plus chemotherapy in locally advanced esophageal squamous cell carcinomaWenqun Xing, Lingdi Zhao, Xiaomin Fu, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|January 1, 2014
Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patientsShuai Wang, Xiaohong Han, Xingsheng Hu, et al.
Immunotherapy|December 15, 2018
Clinical value of neutrophil-to-lymphocyte ratio as a predictor of prognosis of RetroNectin<sup>®</sup>-activated cytokine-induced killer cell therapy in advanced non-small-cell lung cancerLingdi Zhao, Tiepeng Li, Yonghao Yang, et al.
Journal of Oncology|October 31, 2019
Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced MelanomaLingdi Zhao, Yonghao Yang, Baozhen Ma, et al.
Pageof 6